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Sažetak: Cilj: Retinol-vezujući protein 4 (RBP4) je novi adipokin, usko povezan sa insulinskom 
rezistencijom. Međutim, nema dovoljno podataka u literaturi o uticaju menopauze na vrednosti ovog 
proteina u serumu. Zato je cilj ove studije bio da se ispita da li je povezanost menopauze i RBP4 nezavisna 
ili je posredovana insulinskom rezistencijom. Metode: Ukupno 30 žena u premenopauzi i 100 žena u 
postmenopauzi, koje nisu na terapiji su uključene u studiju preseka.  Mereni su antropometrijski i 
biohemijski parametri, kao i krvni pritisak (KP), HOMA indeksi, procenjena jačina glomerularne filtracije 
(JGF) i   izračunati su. Rezultati: Kod žena u postmenopauzi zabeležene su veće vrednosti RBP4 i 
nepovoljniji kardiometabolički profil, u poređenju sa ženama u premenopauzi. Višestruka 
linearnaregresiona analiza je pokazala da su više vrednosti triglicerida (beta=0,315; p=0,002), smanjena 
JGF (beta=-0,258; p=0,004), više vrednosti sistolnog KP (beta=0,418; p=0,028), i menopauza (beta=0,240; 
p=0,016), nezavisni prediktori povišenih vrednosti RBP4 u serumu (R2-adjusted=0,310; F=6,522; 
p<0,001). Zaključak: Menopauza utiče na vrednosti RBP4 u serumu, što treba uzeti u obzir prilikom 
ispitivanja uloge ovog adipokina u pojavi kardiometaboličkih poremećaja. 
Ključne reči: adipokini, insulinska rezistencija, gojaznost, postmenopauza, retinol-vezujući protein 4 
 
Abstract: Aim: Retinol-binding protein 4 (RBP4) is a novel adipokine closely related to insulin 
resistance. However, data on the influence of menopausal status on serum RBP4 are scarce. Therefore, the 
aim of the current study was to examine whether RBP4 levels are associated with menopausal status per 
se, independently of insulin resistance. Methods: A total of 30 premenopausal and 100 postmenopausal 
women non-treated with medications were included in the cross-sectional study. Anthropometric and 
biochemical parameters, as well as blood pressure (BP) were obtained. The homeostasis model 
assessment of insulin resistance (HOMA-IR) and estimated glomerular filtration rate (eGFR) were 
calculated. Results: Postmenopausal women displayed higher RBP4 and an unfavorable cardiometabolic 
profile, compared to premenopausal ones. Multiple linear regression analysis showed that in addition to 
high triglycerides level (beta=0.315; p=0.002), decreased eGFR (beta=-0.258; p=0.004) and high systolic 
BP (beta=0.418; p=0.028), menopause per se is an independent predictor of higher RBP4 levels 
(beta=0.240; p=0.016), (R2-adjusted=0.310; F=6,522; p<0.001). Conclusions: Serum RBP4 levels are 
dependent of menopausal status, which should be taken into account when examining the role of this 
adipokine in cardiometabolic diseases’ occurrence. 
Keywords: adipokines, insulin resistance, obesity, postmenopausal, retinol-binding protein 4 
 
INTRODUCTION 
Women at reproductive age are at a 
lower risk of obesity-related comorbidities, 
compared with postmenopausal women [1]. 
However, a plethora of metabolic disturbances 
accompanied with an increased visceral obesity, 
such as dyslipidemia, insulin resistance, 
hypertension are observed in women after 
menopause [2-5]. 
Having in mind that adipose tissue 
redistributionhas been increasing towards 
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visceral region, along with an 
adipokines secretion, it is speculated that 
postmenopausal women display higher level of 
adipokines than premenopausal ones
Many of these adipokines may impair insulin 
signaling leading to metabolic disorders, making 
them as one of the major culprits for
mellitus type 2 and cardiovascular diseases [
10, 11]. 
One such adipokine is retinol
protein 4 (RBP4), which has been widely studied 
in the recent years [10-12]. Although 
secreted by the liver, adipose tissue also 
represents the highest expression of this
[6]. A majority of studies confirmed an 
independent relationship between RBP4 and 
cardiometabolic states closely related to 
resistance (IR) [9, 10, 12, 13], thus 
obesity-induced IR as a hallmark of increased 
RBP4 levels.The proposed mechanism of such 
relationship may act through down-regulation of 
the insulin responsive glucose transporter
which represents the trigger for RBP4 
adipocytes secretion [6, 11]. 
Additionally, a sexual dimorphism is 
typical for RBP4 secretion, which can be partly 
explained by the influence of sex hormones and 
indirectly, by body fat distribution [14
On the other hand, _our knowledge 
about the influence of menopausal status on 
RBP4 is scarce and the underlying mechanism of 
this relationship is not well elucidated. In line 
with this, the aim of the current study was to 
examine whether RBP4 levels are associated 
with menopausal status, independent of insulin 
resistance. 
 
MATERIALS AND METHODS
Study population 
The current research derived from our 
previous studies examining the utility of 
inflammation and metabolic mark
postmenopausal women [1-5, 11, 15, 16
A total of 30 premenopausal and 100 
postmenopausal women non-treated with 
medications were included in the current cross
sectional study. All women volunteered for 
biochemical analyses check-up in the Center of 
Laboratory Diagnostics of the Primary Health 
Care Center in Podgorica, Montenegro, in a 
period from October 2012 to May 2013.  Women 
were considered to be premenopausal if they 
self-reported regular menstrual cycle, while the 
self-reported absence of menstrual bleeding for 
 
 
     Vol. 42   
  
increased 
 [6-9]. 
 diabetes 
6, 
-binding 
primarily 
 protein 
insulin 
suggesting 
-4, 
]. 
 
ers in 
]. 
-
more than one year was the 
postmenopausal status. 
Inclusion criteria for participants 
enter the study were: premenopausal and 
postmenopausal otherwise healthy women, with 
no signs and symptoms of acute inflammatory 
disease.  
Exclusion criteria were: diabetes 
mellitus, hypothyroidism or hyperthyroidism, 
liver disease other than steatosis, renal 
dysfunction, cardiovascular disorders, 
diseases, high sensitivity C-reactive protein 
(hsCRP) >10 mg/L, smoking, hormone 
replacement therapy or any other medicament 
therapy used in the last six months.
All women that entered the study 
provided written informed consent. T
research was carried out in compliance with the 
Declaration of Helsinki, and with approval of the 
Ethical Committee of Primary Health Care 
Center in Podgorica, Montenegro.
 
Anthropometric measurements
Basic anthropometric measurements, 
such as waist circumference (WC) and body 
mass index (BMI) were obtained, as described 
previously [3]. 
 
Biochemical analyses 
Blood samples were taken and 
biochemical parameterswere measured 
overnight fast of at least 8 hours, as described 
previously [3]. Serum levels of glucose, 
creatinine, and lipid parameters [e.g., total 
cholesterol (TC), high density lipoprotein 
cholesterol (HDL-c), low density 
cholesterol (LDL-c), triglycerides (TG)], 
determined spectrophotometrically (Roche 
Cobas 400, Mannheim, Germany).
hsCRP were determined using an 
immunonephelometric assay (Behring 
Nephelometer Analyzer, BN II, Marburg, 
Germany).Insulin concentration was determined 
by chemiluminescent assay (Immulite 2000, 
Siemens, Muenchen, Germany). 
estimated glomerular filtration rate (eGFR) were
calculated, as described elsewhere [2
Blood pressure was measured 
described elsewhere [2]. 
 
Statistical analysis 
Testing distributions of examined 
variables were performed by Kolmogorov
Smirnov test. Data were shown as 
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mean±standard deviation for normally 
distributed variables. Log-normally distributed 
variables were presented as geometric mean 
(95% Confidence Interval) [17]. A comparison of 
normal and log-normal continuous variables 
were done by Student’s t-test. Skewed 
distributed data were given as median 
(interquartile range) and compared by Mann-
Whitney test. Spearman's correlation analysis 
was used to estimate correlations between the 
examined parameters in pre- and 
postmenopausal women. Data from correlation 
analysis were presented as coefficient 
correlation, rho (ρ). If probability values (p) for 
ρ were less than 0.1, those variables 
(independent) were tested in further multiple 
linear regression analysis. As well, skewed 
distributed data were not included as 
independent variables. Multiple linear 
regression analysis was performed to estimate 
the independent contribution of clinical 
parameters, and presence of menopausal status 
on RBP4 level. Categorical data referring to 
menopausal status were included in the Model 
and coded as 1-premenopausal status and 2-
postmenopausal status. The F-ratio of the 
ANOVA test in multiple linear regression 
analysis was used to determine whether the 
overall regression model is a good fit of the data. 
Multicollinearity among independent variables 
was also tested. Statistical analyses were 
performed using PASW® Statistic version 18 
(Chicago, Illinois, USA) and MedCalc version 15.8 
softwares. All statistical tests were considered 
significant when p was less than 0.05. 
 
RESULTS 
Baseline clinical and 
laboratorycharacteristics according to 
menopausal status are summarized in Table 1. 
Postmenopausal women were older and 
displayed higher DBP than premenopausal. 
There were none significant differences in BMI, 
WC and SBP between tested groups (Table 1). 
Furthermore, postmenopausal women 
had higher TC, LDL-c, TG concentrations and 
HOMA-IR than premenopausal women (Table 1). 
Also, statistically higher levels of RBP4 were 
determined in postmenopausal women. 
Estimated GFR was significantly lower in 
postmenopausal women, but as it can be seen 
from the Table 1, both groups of women had 
preserved kidney function.  
 
 
Table 1. Baseline clinical and laboratory characteristics of women according to menopausal status 
Tabela 1. Klinički i laboratorijski parametri ispitanica u odnosu na menopauzu 
 Premenopausal women Postmenopausal women p 
N 30 100  
Age, years 47.56 (46.74-48.39) 56.52 (55.68-57.38) <0.001 
    
BMI, kg/m2 25.52 (23.49-27.72) 26.41 (25.65-27.19) 0.342 
    
WC, cm 85.40 (79.78-91.43) 89.25 (87.12-91.43) 0.146 
    
SBP, mmHg 125.00 (118.00-132.00) 128.00 (124.00-134.00) 0.480 
    
DBP, mmHg 76.00 (73.00-81.00) 83.00 (80.00-86.00) 0.021 
HDL-c, mmol/L 1.68±0.42 1.66±0.42 0.820 
LDL-c, mmol/L 3.59 ±1.17 4.41 ±1.05 <0.001 
TG, mmol/L 1.09 (0.94-1.26) 1.37 (1.26-1.49) 0.015 
Glucose, mmol/L* 5.40 (5.10-5.80) 5.30 (5.00-5.70) 0.606 
Insulin, μIU/L** 6.40 (5.05-8.10) 6.71 (6.13-7.35) 0.668 
HOMA-IR** 1.53 (1.20-1.97) 1.61 (1.46-1.77) 0.001 
Creatinine, µmol/L* 56.50 (53.36-59.57) 57.00 (51.00-62.00) 0.861 
eGFR, 
mL/min/1.73 m²** 
105.65 (100.58-10.97) 99.72 (98.50-100.96) 0.001 
HsCRP, mg/L** 0.80 (0.52-1.23) 0.99 (0.83-1.18) 0.311 
RBP4, mg/L* 34.47 (35.16-39.94) 43.24 (41.95-44.58) <0.001 
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Data are presented as an arithmetic mean ± SD and compared 
*Skewed distributed data are presented as median (interquartile range) and compared with 
Whitney U test 
**Log-normal distributed data are presented as geometric mean (9
test after logarithmic transformation 
BMI-Body mass index; WC-Waist circumference; SBP
pressure; TC-Total cholesterol; HDL-c
cholesterol; TG-Triglycerides; HOMA
Estimated glomerular filtration rate; hsCRP
protein 4 
 
Associations of examined parameters 
with RBP4 were tested with Spearman
correlation analysis. Significant positive 
correlations were determined between RBP4 
 
Table 2. Spearman’s correlation analys
Tabela 2. Spirmanova korelacija između RBP4, 
 
 
Age, years 
BMI, kg/m2 
WC, cm  
SBP, mmHg 
DBP, mmHg 
TC, mmol/L 
HDL-c, mmol/L
LDL-c, mmol/L
TG, mmol/L 
Glucose, mmol/L
Insulin, μIU/L
HOMA-IR 
Creatinine, µmol/L
eGFR, mL/min/1.73 m²
HsCRP, mg/L
Data are presented as correlation coefficient Rho (ρ)
BMI-Body mass index; WC-Waist circumference; SBP
pressure; TC-Total cholesterol; HDL-c
cholesterol; TG-Triglycerides; HOMA
Estimated glomerular filtration rate; hsCRP
protein 4 
 
Further statistical testing included 
multiple linear regression analysis in order to 
identify the demographic and clinical 
parameters independently associated with RBP4 
(Table 3). Independent variables that correlated 
with RBP4 levels in Spearman’s correlation
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to Student’s t-test 
5% CI) and compared with Student’s t
-Systolic blood pressure; DBP-Diastolic blood 
-High density lipoprotein cholesterol; LDL-c-Low density lipoprotein 
-IR-Homeostasis model assessment of insulin resistance; eGFR
-High-sensitivity C-reactive protein; RBP4-
’s 
and age, BMI, WC, SBP, DBP, TC, LDL
glucose, insulin, HOMA-IR, creatinine (Table 2
On the contrary, RBP4 significantly negatively 
correlated with HDL-c and eGFR. 
is between RBP4 and clinical and laboratory parameters in all 
women 
kliničkih i laboratorijskih parametara u celoj grupi 
ispitanica 
RBP4, mg/L 
ρ p 
0.255 0.002 
0.252 0.002 
0.255 0.002 
0.389 <0.001 
0.381 <0.001 
0.212 0.009 
 -0.290 <0.001 
 0.256 0.002 
0.452 <0.001 
 0.215 0.008 
 0.165 0.041 
0.188 0.022 
 0.250 0.002 
 -0.361 <0.001 
 0.081 0.324 
 
-Systolic blood pressure; DBP-Diastolic blood 
-High density lipoprotein cholesterol; LDL-c-Low density lipoprotein 
-IR-Homeostasis model assessment of insulin resistance; eGFR
-High-sensitivity C-reactive protein; RBP4-
 
analysis with the significance of p<0.1 (Table 2) 
and which were not skewed distributed after 
tested by Kolmogorov-Smirnov test, entered into 
the Model. Although, insulin concentration was 
used in HOMA-IR calculation, it was not included 
into the Model. Also, because of glucose and WC 
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skewed distributions, these parameters were 
not included into the Model. According to the 
ANOVA test of multiple linear regression 
analysis, tested independent variables 
statistically significantly predicted RBP4 
concentration, F=6,522, p<0.001. This also 
demonstrated the Model is a good fit of the data. 
An adjusted R2=0.310 for the Model 
demonstrated that 31% variation in RBP4 
concentration could be explained by this Model. 
SBP was independently associated with an 
increase in RBP4 levels (β=0.418, p=0.028), as 
well as TG levels (β=0.315, p=0.002). On the 
other hand, eGFR was independently associated 
with decrease in RBP4 levels (β= - 0.258, 
p=0.004). The independent positive association 
of menopausal status and RBP4 concentration, 
with standardized coefficient β=0.240, p=0.016 
was of the greatest importance.The multiple 
regression unstandardized coefficient (B), its 
standard error (SE), standardized coefficient (β) 
and p levels are presented in Table 3. 
 
Table 3.Multiple linear regression analysis of the association of RBP4 with examined parameters 
Tabela 3. Višestruka linearna regresija povezanosti RBP4 sa ostalim ispitivanim parametrima 
Predictors Unstandardized Standardized 
coefficient 
 
 B Standard error β p 
Age, years -0.155 0.175 -0.091 0.376 
BMI, kg/m2 -0.073 0.096 -0.072 0.446 
SBP, mmHg 0.385 0.174 0.418 0.028 
DBP, mmHg -0.299 0.199 -0.291 0.135 
HDL-c, mmol/L -0.004 0.018 -0.020 0.843 
LDL-c, mmol/L 0.002 0.005 0.024 0.760 
TG, mmol/L 0.123 0.040 0.315 0.002 
HOMA-IR -0.007 0.029 -0.021 0.817 
eGFR, mL/min/1.73 m² -0.536 0.181 -0.258 0.004 
Menopausal status 0.047 0.019 0.240 0.016 
 
BMI-Body mass index; SBP-Systolic blood pressure; DBP-Diastolic blood pressure; HDL-c-High density 
lipoprotein cholesterol; LDL-c-Low density lipoprotein cholesterol; TG-Triglycerides; HOMA-IR-
Homeostasis model assessment of insulin resistance; eGFR-Estimated glomerular filtration rate; RBP4-
Retinol-binding protein 4 
 
DISCUSSION 
The main result of our study is that 
menopause per se has an independent influence 
on higher RBP4 levels (Table 3). Also, 
postmenopausal women in the current study 
displayed significantly higher levels of this 
adipokine than premenopausal counterparts 
(Table 1). Similarly, some previous researchers 
also reported higher RBP4 in postmenopausal 
women [7-9]. 
The higher RBP4 concentration in 
postmenopausal women in our study may in 
part be explained by estrogen deficiency. In line 
with this, an inverse relationship between 
serum RBP4 and estradiol levels in a cohort of 
obese women, was recently reported [18]. The 
indirect effect of estrogen may be exerted 
through the influenceof the body fat 
distribution on serum RBP4. Estrogen levels are 
related to reduced fat storage and 
increasedenergy expenditure[14]. In line with 
that, it was shown that ovariectomy was 
accompanied with an increase weight gain in 
response to a high-fat diet in female mice in 
comparison with mice on a normal-fat diet [14]. 
On the contrary, supplementation of 17-β 
estradiol (E2) had no effect on male mice, but 
only on female mice [19], suggesting sex 
difference in body fat distribution, mainly due 
to estrogen influence. 
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In addition, animal and human studies 
showed that lack of endogenous estrogen 
production leads to IR [14]. Furthermore, E2 
replacement therapy in postmenopausal 
women is related to enhanced insulin signaling 
through suppression of lipolysis [20]. Namely, i
is well established that obesity is accompanied 
with increased IR and unfavorable lipid profile 
[15]. Although in the current study there were 
no significant difference in anthropometric 
parameters between pre- and postmenopausal 
women,  the latter ones showed higher HOMA
IR, TC, LDL-c, and TG than premenopausal ones 
(Table 1). 
In our study, in addition to SBP, TG and 
eGFR, menopausal status exerted the 
independent influence on RBP4 (Table 3
may in part be explained by diminished effect of 
estrogen to suppress the lipolysis through 
activation of estrogen receptor alpha (ER
adipose tissue [19], thus suggesting the 
contribution of increased lipolysis and 
subsequent free fatty acid secretion from 
adipose tissue in insulin resistance occurrence 
and progression in postmenopausal women
Additionally, in Spearman’s non
parametric correlation analysis, RBP4 
correlated with anthropometric and 
cardiometabolic parameters (Table 2
However, we failed to show the direct influence 
of anthropometric parameters on RBP4 levels. 
Our results are in line with the study of Tan et 
al. [21] who showed that RBP4 mRNA 
expression was significantly increased in 
human adipocytes of overweight women with 
polycystic ovary syndrome, but they 
the influence of anthropometric indices on 
higher RBP4 mRNA expression and higher 
RBP4 levels in circulation.  
Our study has some limitations,
the relatively small sample size of examined
cohorts and its cross-sectional design. In 
addition, we were not able to determine
hormones in our study group. However, o
cohort comprised of premenopausal and
postmenopausal otherwise healthy 
without hormone replacement therapy or any 
medication usage in the last six months, so we 
excluded such confounding factors when 
estimating cardiometabolic profile of examined 
groups. In addition, we also exclud
cardiometabolic diseases that may also affect 
serum RBP4 level. Future longitudinal studies 
with larger sample size are needed to further 
2 4  
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CONCLUSION 
Postmenopausal women displayed 
higher retinol-binding protein 4 and 
unfavorable cardiometabolic profile, compared 
to premenopausal ones. Menopause per se is 
independent predictor of high 
binding protein 4levels which should be taken 
into account when examining the role of thi
adipokine in cardiometabolic disease 
occurrence. 
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